home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ResMed Inc. Common Stock (NY:RMD)

225.99 -1.42 (-0.62%)

Official Closing Price Updated: 7:00 PM EDT, Mar 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ResMed Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

ResMed (NYSE:RMD) Posts Better-Than-Expected Sales In Q4 But Stock Drops

January 31, 2025

Medical device company ResMed (NYSE:RMD) announced better-than-expected revenue in Q4 CY2024, with sales up 10.3% year on year to $1.28 billion. Its non-GAAP profit of $2.43 per share was 5.2% above...

Via StockStory

In today's session, there are S&P500 stocks with remarkable trading volume. ↗

January 31, 2025

Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below.

Via Chartmill

Top S&P500 movers in Friday's session ↗

January 31, 2025

Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Tech Stocks Rally, S&P 500 Flirts With Records, Gold Extends All-Time Highs: What's Driving Markets Friday? ↗

January 31, 2025

Major stock indices have completed their recovery following Monday's sharp drop, buoyed by tech stocks rallying on the back of solid earnings and positive macroeconomic data. The S&P 500 index stands...

Via Benzinga

Topics Stocks

ResMed Earnings Analysis: Q2 Recap ↗

January 30, 2025

Via Benzinga

Friday's session: gap up and gap down stock in the S&P500 index ↗

January 31, 2025

Stay updated with the S&P500 gap up and gap down stocks on Friday. Get a glimpse of the market's movement during today's session.

Via Chartmill

ResMed: Digital Health Drives Q2 Growth ↗

January 30, 2025

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth in revenue and profitability.

Via The Motley Fool

ResMed, In A Buy Zone, Stays Flat After Handily Beating Earnings Views ↗

January 30, 2025

The company easily beat earnings expectations, while sales were narrowly above.

Via Investor's Business Daily

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2025

January 30, 2025

From ResMed Inc.

Via GlobeNewswire

Reasonable Growth, Debt Levels, and a High ROIC Make RESMED INC (NYSE:RMD) Appealing to Quality Investors. ↗

January 28, 2025

A fundamental analysis of (NYSE:RMD): Why Quality-Oriented Investors Should Consider NYSE:RMD.

Via Chartmill

What 5 Analyst Ratings Have To Say About ResMed ↗

January 10, 2025

Via Benzinga

Should you consider RESMED INC (NYSE:RMD) for quality investing? ↗

November 29, 2024

RESMED INC (NYSE:RMD) may be suited for quality investing, we'll explore why in this article.

Via Chartmill

Why Quality-Oriented Investors Should Consider NYSE:RMD. ↗

November 07, 2024

Exploring RESMED INC (NYSE:RMD)'s quality characteristics.

Via Chartmill

Wall Street Remains Flat, Microsoft Eyes Heaviest Drop Since Late 2022, Gold Sets Fresh Records: What's Driving Markets Thursday? ↗

January 30, 2025

Wall Street is struggling to find risk-on momentum, with major indexes stuck near the flatline at midday as investors assess the latest earnings reports from mega-cap tech stocks and...

Via Benzinga

This AppLovin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

January 10, 2025

Via Benzinga

ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025

January 09, 2025

From ResMed Inc.

Via GlobeNewswire

P/E Ratio Insights for ResMed ↗

October 28, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For ResMed ↗

October 25, 2024

Via Benzinga

Earnings Scheduled For January 30, 2025 ↗

January 30, 2025

Via Benzinga

ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

January 06, 2025

From ResMed Inc.

Via GlobeNewswire

Top Stock Reports For UnitedHealth, Costco & IBM ↗

January 03, 2025

Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Inc., Costco Wholesale Corp., and International Business Machines Corp., as well as a micro-cap...

Via Talk Markets

Topics Stocks / Equities

Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive? ↗

December 20, 2024

Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.

Via Investor's Business Daily

This AutoZone Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

December 13, 2024

Via Benzinga

ResMed Is 80 And 80: Hits 80-Plus Relative Strength Rating After Rising 80% In A Year ↗

November 18, 2024

ResMed also boasts a superb 96 EPS Rating out of 99, putting it in the top 4% of all companies for recent and long-term profit growth.

Via Investor's Business Daily

ResMed Announces Participation in the UBS Global Healthcare Conference

November 05, 2024

From ResMed Inc.

Via GlobeNewswire

Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review ↗

October 25, 2024

The major indexes were mixed for the week.

Via Investor's Business Daily

Tech Stocks Rally As Investors Await Magnificent 7 Earnings; Dollar Eyes Fourth Straight Positive Week: What's Driving Markets Friday? ↗

October 25, 2024

Stocks are ending the week on a high note, with tech leading the charge as investors position ahead of next week’s pivotal earnings releases from five of the “Magnificent Seven” stocks.

Via Benzinga

Sleep Apnea Device Maker ResMed Is A Durable MedTech, With Positive Fundamentals, Says Analyst ↗

October 25, 2024

ResMed reports Q1 2025 adjusted EPS of $2.20, up 34%, beating estimates. Revenue reached $1.22 billion, up 11%, driven by demand growth.

Via Benzinga

My 3 Favorite Stocks to Buy Right Now ↗

October 25, 2024

Here are three attractive stocks to buy that will give you a healthy mix of growth and dividends.

Via The Motley Fool

Obesity Drugs-Tied ResMed Edges Higher On Quarterly Beat ↗

October 24, 2024

The company beat fiscal first-quarter expectations. Shares are forming a flat base.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com